| Autor: |
Qing Zhu, McLellan, Jason S., Kallewaard, Nicole L., Ulbrandt, Nancy D., Palaszynski, Susan, Jing Zhang, Moldt, Brian, Khan, Anis, Svabek, Catherine, McAuliffe, Josephine M., Wrapp, Daniel, Patel, Nita K., Cook, Kimberly E., Richter, Bettina W. M., Ryan, Patricia C., Yuan, Andy Q., Suzich, JoAnn A. |
| Předmět: |
|
| Zdroj: |
Science Translational Medicine; 5/3/2017, Vol. 9 Issue 388, p1-11, 11p |
| Abstrakt: |
The article discusses the development of monoclonal antibody MEDI8897 as a potential respiratory syncytial virus (RSV) prophylaxis for all infants. It mentions that the prevention of RSV illness in all infants is considered as a major public health priority wherein palivizumab is the only approved agent for RSV prophylaxis. It notes that the pharmacokinetics of palivizumab in infants supports the development of MEDI8897 as a cost-effective option to protect all infants from RSV disease. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
